Selected articles from The Arising’s October 23, 2026 research edition.
A supplement can change a biological measure without delivering the hoped-for benefit. A diet can change weight without answering every question about strength. These articles from October 23 ask what the evidence actually measured—and what remains to be shown before a longevity promise becomes useful.
Fish oil reached the brain. The hoped-for benefit did not follow.
A two-year DHA trial separates biological activity from clinical benefit
High-dose DHA supplementation changed a biological measure in a randomized trial of older adults at risk for dementia. Over two years, however, the researchers did not observe better cognition or brain-volume outcomes than with placebo. The distinction is central to longevity medicine: reaching a target is not the same as improving a life.
The phase IIa trial, published in EBioMedicine, enrolled 365 adults aged 55 to 80 at the University of Southern California. They did not have dementia, consumed little dietary DHA and had at least one dementia risk factor. Participants were randomly assigned to 2 grams of DHA daily or placebo for 24 months. The study was double-blind.
DHA is an omega-3 fatty acid. Nearly half the participants carried APOE ε4, a genetic variant associated with increased Alzheimer's risk. Researchers were interested in whether supplementation could change DHA availability in the central nervous system, including among carriers.
What the trial was designed to establish
The primary outcome was a change in the ratio of DHA to arachidonic acid in cerebrospinal fluid at six months. Participants willing to undergo lumbar puncture contributed to that measurement. The ratio increased with DHA compared with placebo, and the difference did not depend on APOE ε4 status.
That was evidence of biological target engagement. It showed that the intervention changed the intended biochemical measure. It did not by itself establish prevention of Alzheimer's disease.
What did not improve
Over 24 months, the researchers found no treatment differences in cognitive performance or brain volumes. Brain imaging was a secondary outcome, and cognition was exploratory. These distinctions matter: the study was built primarily to test the biochemical question rather than to deliver a definitive verdict on every possible clinical benefit.
Dropout was 38%, largely related to COVID-19. That is a substantial limitation. The trial also studied a particular population, dose and formulation. It cannot stand in for every use of omega-3 products, every dietary pattern or every stage of cognitive illness.
The absence of a detected benefit is not a demonstration that fish is useless or that a whole dietary pattern has no value. Those are different questions. Nor should the result be repackaged as proof that the supplement prevented decline simply because a blood or spinal-fluid marker changed.
The lesson for longevity
The study makes a valuable demand of future interventions: show what happens beyond the mechanism. Better biological access can be an important step, but people ultimately care about memory, independence and daily function.
The investigators suggest that future research should focus on how the brain handles DHA. For readers, the immediate implication is to distinguish the reason a supplement might work from evidence that it delivers the outcome being promised. Decisions about an existing treatment or supplement should account for its actual indication and a person's clinical circumstances.
Read the research: Primary study / PubMed
Study publication: July 2026. Source edition: October 23, 2026.
Fasting and muscle: the unanswered part of the weight-loss story
Small short-term differences in lean mass do not settle long-term function
A lower number on the scale can hide several different changes. Fat may fall, but so may water or lean tissue. For people in midlife and later life, preserving the ability to move and function matters alongside weight loss. A scoping review of intermittent fasting makes that unresolved question visible.
Santero and colleagues reviewed 20 randomized controlled trials involving 1,653 adults aged 45 and older. About 64% were women, and most participants had overweight or obesity. Published in Advances in Nutrition, the review mapped the evidence rather than pooling every study into a single effect estimate.
Trials had to study fasting for at least four weeks and measure body composition with validated methods. People with diseases causing muscle loss were excluded. The comparisons included a habitual diet and continuous calorie restriction—eating less overall without the same fasting schedule.
What the short trials suggest
Across the durations studied, commonly 12 weeks or less, differences between groups in total fat-free mass were generally small. Intermittent fasting produced weight, fat-mass and waist reductions comparable to continuous calorie restriction. Compared with habitual eating, reductions in weight and fat were reported more consistently with fasting.
The fasting approaches varied, including alternate-day regimens, modified fasting days and time-restricted eating. That variety is one reason the results should not become a blanket promise about a particular fasting window.
Lean mass is not the whole muscle story
Fat-free mass includes more than skeletal muscle. It also includes organs, bone and water. Most studies used DXA or bioelectrical impedance, so a finding about total lean mass cannot simply be translated into a finding about muscle strength or physical capability.
Strength, physical performance and quality of life were rarely assessed. Evidence on protein intake, insulin-related outcomes and the combination of fasting with exercise was limited and varied. Data on adults in advanced age were particularly sparse.
Those gaps matter because the question is not only what a body weighs after a few weeks. It is whether someone maintains strength, mobility and reserve over months and years. A short-term similarity between diets cannot settle that longer-term question.
What a stronger answer would require
The authors concluded that the available evidence does not permit definitive conclusions about preservation of fat-free mass, particularly over the long term in older adults. The review therefore offers context, not proof that fasting protects muscle or is safe for everyone.
Longer studies need standardized muscle and functional measurements, with clearer attention to nutrition and exercise. In practice, choosing a weight-loss approach requires attention to the whole person, including medications, nutritional needs and the capacity one hopes to preserve. The worthwhile goal is a change that supports life beyond the scale.
Read the research: Primary study / PubMed
Study publication: July 2026. Source edition: October 23, 2026.
Evidence note: Publication records and abstracts were checked during the October 25 preparation; this is not a completed full-text appraisal of every study. Publication dates are distinguished from edition dates.
Alive. Awake. Aware.
This is The Arising.
John Griffin, MD
Educational reading, not personal medical advice.